Biotech deal­mak­er Ra­maswamy rais­es an­oth­er $55M for Ax­o­vant

One of biotech’s most promi­nent wheel­ers and deal­ers just nabbed an ex­tra $55 mil­lion to push along the pipeline at the neu­ro­sciences play­er Ax­o­vant.

Vivek Ra­maswamy, who’s been whip­ping up new com­pa­nies and rais­ing hun­dreds of mil­lions of dol­lars in IPOs, inked a debt fi­nanc­ing deal with Her­cules Cap­i­tal. Ra­maswamy will start off pay­ing in­ter­est for 18 months, then is in line to be­gin pay­ing back prin­ci­pal as well.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.